16.2% Market Share in July
Listed with Top 3 PBMs Right After Launch
Swift Reimbursement Coverage Proves Effective
Yuflyma and Truxima Also Show Robust Performance

Celltrion's autoimmune disease treatment 'Stekima' (ingredient name: ustekinumab) continues to show a sharp increase in prescriptions in the United States, the world's largest pharmaceutical market. As prescriptions for high-margin follow-up products are expanding in the U.S. and new product launches are planned, Celltrion's performance is expected to grow even more rapidly.

Product image of Celltrion's autoimmune disease treatment 'Stekima'. Celltrion

Product image of Celltrion's autoimmune disease treatment 'Stekima'. Celltrion

View original image

According to IQVIA, a pharmaceutical market research firm, Stekima maintained its leading position among biosimilar prescriptions by achieving a U.S. market share of 16.2% in July. After reaching double digits with a 10.2% market share in February this year, just about a year after its launch, it gained another 6 percentage points in five months, further widening the gap with competing products.


This performance is mainly attributed to the locally tailored sales strategy implemented by Celltrion's U.S. subsidiary. From the initial launch, Stekima secured rapid reimbursement coverage by being listed as a preferred drug in the formularies of the three largest pharmacy benefit managers (PBMs) in the U.S., as well as those of public and private insurance plans managed by major PBMs ranked within the top five by size. The networks with key stakeholders, including local autoimmune disease specialists and insurance companies, have continued to strengthen, while the distribution channels are being operated stably. As a result, Celltrion's growth trajectory in the U.S. market is expected to accelerate further.


Another autoimmune disease treatment, 'Yuflyma' (ingredient name: adalimumab), also recorded a 9.4% share during the same period. Celltrion explained that this was largely due to the active utilization of the infrastructure already established in the autoimmune disease sector. At the end of last year, Yuflyma further expanded its core coverage by being added to the public insurance formularies of two of the three largest PBMs in the U.S.


Celltrion's existing product lines are also performing steadily based on solid prescription results in the U.S. 'Truxima' (ingredient name: rituximab), a treatment for blood cancer, maintained the No. 1 position in prescriptions for six consecutive months, with a market share of 38.6%. Given that Truxima became the first rituximab biosimilar to receive the status of 'interchangeability'—allowing substitution for the original drug—from the FDA last month, the company expects this strong prescription trend to continue. 'Inflectra' (the U.S. brand name for 'Remsima') also holds a leading position among biosimilar prescriptions with a 30.7% market share.



A Celltrion representative said, "Stekima, which has secured a spot among front-runners in market share, along with both new and existing product lines, are all delivering significant results in the U.S. By maximizing the effectiveness of the direct sales network we have established, we will accelerate the expansion of prescriptions. Moving forward, we are committed to successfully launching high-margin follow-up products such as Omliclo, in order to achieve sales growth in the U.S. market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing